全球經前綜合症治療市場 - 2022-2029

市場動態

全球經前綜合徵治療市場的推動力來自於全球對經前綜合徵治療重要性的認識不斷提高、政府和非政府組織加大力度解決女性保健問題以及開發新的治療方法。幾個因素。

預計龐大的目標人群和新治療方法的開發將成為市場增長的驅動力。

由於它是育齡婦女最常見的健康問題，龐大的目標人群推動了市場。 Petranka Chumpalova 等人在 2020 年發表在《普通精神病學年鑑》上的一項研究發現，90% 的育齡婦女會出現從輕微到嚴重的經前綜合徵症狀。經證實，其中約 20-40% 的人患有經前綜合症，其中約 2-8% 的人患有經前煩躁症 (PMDD)。

開發經前綜合症治療方法的研發活動預計將對市場產生積極影響。例如，與安慰劑相比，通過 PRN 鼻內給藥的 PH80-PMD（Ferrin Pharma）在關鍵的經前期表現出中度至重度經前期綜合徵症狀，而無需長期給藥。臨床試驗表明，它顯著降低

Asalina Pharma 正在開發一種很有前景的產品，用於治療痛經 (PMDD)，這是一種嚴重的致殘性經前期綜合徵。該公司的旗艦產品 Cepranolon 在一項針對 120 名經前焦慮症女性的新 II 期研究中達到了主要安全性和有效性終點。 Sepraolone 是一種一流的內源性小分子化合物，可作為 GABA-A 調節類固醇拮抗劑 (GAMSA)。

全世界對經前綜合症診斷、治療和醫療費用的認識正在提高。例如，2019年6月，經前煩躁症（PMDD）被賦予了獨特的分類代碼，並在WHO新的國際疾病分類ICD-11中首次明確將其歸類為婦科疾病而非精神疾病。我是。將 PMDD 納入 ICD-11 是一個重要指標，表明全球對 PMDD 的醫學意識不斷提高，科學界越來越一致認為 PMDD 是一種激素而不是精神疾病。世界衛生組織目前的 ICD-10 也提到了 PMDD，但間接地作為“經前緊張綜合徵”的一個子類。

與使用治療劑相關的副作用預計會阻礙市場增長。

但是，與使用經前期綜合徵藥物相關的副作用可能會阻礙市場增長。例如，使用選擇性 5-羥色胺再攝取抑製劑 (SSRI) 會導致噁心、虛弱、疲勞、性功能障礙和精力不足等不良事件。不建議長期使用促性腺激素釋放激素 (GnRH) 類似物，因為它們會對骨密度產生不利影響並增加發生骨變薄的風險。

行業分析

全球經前綜合症治療市場根據波特五力、監管分析、供應鏈分析和定價分析等各種行業因素對市場進行了深入分析。

全球經前綜合症治療市場報告提供了大約 45 多個市場數據表、40 多個數字和 180 頁的組成。

內容

第一章研究方法與範圍

• 調查方法
• 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

• 市場影響因素
  • 驅動程序
    • 擴大目標人群
    • 治療方法的開發
  • 約束因素
    • 抑制因素：與使用治療劑相關的副作用
  • 商機
  • 影響分析

第五章行業分析

• 波特五力分析
• 監管分析
• 供應鏈分析
• 定價分析

第 6 章按藥物類別

• 止痛藥
• 抗抑鬱藥
• 口服避孕藥
• 卵巢抑製劑
• 促性腺激素釋放激素 (GnRH) 類似物
• 僅含雌激素的貼片和植入物
• 選擇性血清素再攝取抑製劑 (SSRI)
• 其他

第 7 章按銷售渠道

• 醫院藥房
• 藥店和零售藥店
• 在線提供商
• 其他

第 8 章按地區

• 北美
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 意大利
  • 西班牙
  • 其他歐洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳大利亞
  • 其他亞太地區
• 中東和非洲

第 9 章競爭格局

• 主要發展和戰略
• 公司份額分析
• 治療分類基準
• 值得關注的重點公司列表

第 10 章公司簡介

• Bayer AG
  • 公司概況
  • 藥物類別組合和說明
  • 主要亮點
  • 財務摘要
• Eli Lilly And Company
• GlaxoSmithKline Plc.
• H. Lundbeck A/S
• Pfizer Inc.
• Asarina Pharma AB
• Chattem, Inc.（Sanofi）
• Dekk-Tec
• Pherin Pharmaceuticals
• Novartis International AG

第 11 章全球經前綜合徵治療市場-DataM

Market Overview

Premenstrual Syndrome Treatment Market size was valued US$ 1,367 million in 2021 and is estimated to reach US$ 1,829 million by 2029, growing at a CAGR of 4.1% during the forecast period (2022-2029).

Premenstrual Syndrome is a combination of physical and emotional symptoms, including mood swings, body pain, fatigue, tender breasts, food cravings, fatigue, irritability, and depression. It arises around the end of the luteal phase and dissipates with menstruation or briefly thereafter. It is most commonly observed among women with a high level of stress, depression, cyclic changes in the menstruation cycle, and chemical changes in the brain.

Market Dynamics

The global premenstrual syndrome treatment market is growing due to several factors such as growing awareness towards the significance of premenstrual syndrome treatment globally and rising government and non-government organizations initiatives doe women healthcare and various developments of new therapies.

Larger targeted population and new developments in therapies are expected to drive market growth.

The larger targeted population drives the market as it is the most common health problem in women of reproductive age. According to Petranka Chumpalova et al. 2020, in a study published in the Annals of General Psychiatry journal, 90% of women of reproductive age experience several premenstrual symptoms varying from mild to severe. Approximately 20-40% of those women suffer from Premenstrual Syndrome, and around 2-8% of those women suffer from the premenstrual dysphoric disorder (PMDD) worldwide.

The undergoing research and development activities to develop therapies for Premenstrual Syndrome shall positively impact the market. For instance, the clinical studies demonstrated that the administration of the PH80-PMD (Pherin Pharmaceuticals) administered intranasally PRN decreased moderate and severe premenstrual symptoms significantly better compared to the placebo during the critical premenstrual days of the cycle without the need for chronic administration.

Asarina Pharma is developing a potential therapy for the treatment of Premenstrual Dysphoric Disorder (PMDD), a severe and disabling form of premenstrual syndrome. Its lead product, i.e., Sepranolone, had met its primary safety and efficacy endpoints in a new Phase II study involving 120 women with Premenstrual Dysphoric Disorder. Sepranolone is a proprietary, first-in-class, endogenous, small molecule that acts as a GABA-A modulating steroid antagonist (GAMSA).

There is an increase in awareness regarding the diagnosis, treatment, and reimbursement of premenstrual syndrome worldwide. For instance, in June 2019, Premenstrual dysphoric disorder (PMDD) has been given its own classification code and, for the first time, classified clearly as a gynecological, not mental, disease in the WHO's new International Classification of Diseases, ICD-11. The inclusion of PMDD in ICD-11 is an important indicator of the growing medical awareness of PMDD worldwide and a growing scientific consensus that PMDD is a hormonal, not psychiatric condition. PMDD is mentioned in the WHO's present ICD-10, but indirectly as a sub-classification under 'Premenstrual tension syndrome.

Side-effects associated with use of therapies are expected to hamper the market growth.

However, the side-effects associated with the use of therapies for premenstrual syndrome shall hider market growth. For instance, the use of selective serotonin reuptake inhibitors (SSRIs) results in adverse events such as nausea, asthenia, fatigue, sexual dysfunction, and decreased energy. Gonadotropin-releasing hormones (GnRH) analogs are not recommended for the long term as these analogs lead to adverse effects on bone density and increase the risk of developing bone thinning.

Industry Analysis

The global premenstrual syndrome treatment market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis.

Segment Analysis

Product type segment is expected to hold the largest market share in global premenstrual syndrome treatment market

The premenstrual syndrome treatment market is segmented based on product type as analgesics, antidepressants, oral contraceptives agents, ovarian suppression agents, gonadotropin-releasing hormone (GnRH) analogs, estrogen-only patches & implants, selective serotonin reuptake inhibitors (SSRIs), and others. The analgesics segment accounts for the highest market share owing to the higher uptake of analgesics as it is the mainstay treatment for premenstrual syndrome. Various analgesics such as ibuprofen, acetaminophen, diclofenac, naproxen is used for the management of premenstrual syndrome. These analgesics are effective in reducing stomach cramps, headache, muscle pain, joint pain and others.

The oral contraceptive agent segment is expected to have positive market growth due to the rising usage of oral contraceptive agents to manage the physical and psychiatric symptoms of premenstrual syndrome. The oral contraceptive agents, including the levonorgestrel/ Ethinyl estradiol, drospirenone and others, are used to even out the ovarian hormone fluctuations. Clinical studies have demonstrated that the administration of 90 mcg levonorgestrel/20 mcg Ethinyl estradiol resulted in improvement in depressive and physical symptoms.

The antidepressant segments account for the significant market share over the forecasted period. The antidepressants act by increasing the brain chemicals, including opioids, serotonin, and others hampered due to the ovarian hormones. Serotonin reuptake inhibitors (SSRIs) are recommended for treating the mood changes associated with Premenstrual Syndrome. The market is dominated by the availability of several serotonin reuptake inhibitors, including Fluoxetine (Prozac), paroxetine (Paxil), Sertraline (Zoloft), citalopram (Celexa) and escitalopram (Lexapro) for the treatment of psychiatric symptoms associated with Premenstrual Syndrome. The clinical studies demonstrated that these five serotonin reuptake inhibitors (SSRIs) have statistically significant benefits on patient-reported symptoms when taken continuously or only during the luteal phase.

Further, the market is also classified based on distribution channel as hospital pharmacies, drug stores & retail pharmacies, online providers, and others. The drug stores & retail pharmacies segment are expected to have the highest market share due to many drug stores & retail pharmacies worldwide. The majority of the drugs being used for the premenstrual syndrome are the counter drugs, which are easily available over the counter without a prescription. It is further expected that the drug stores & retail pharmacies segment shall lose its market share with the rising growth of online providers worldwide over the forecasted period.

The online provider's segment is expected to have significant market growth due to the growing preference for online purchasing of drugs compared to the traditional methods, including the drug stores & retail pharmacies and hospital pharmacies. The rising awareness regarding online providers, growing internet users, and digital transformation shall stimulate market growth. Hence, it is expected that online providers shall account for the highest market share over the forecasted period.

Geographical Analysis

North America region holds the largest market share in the global premenstrual syndrome treatment market

By region, the premenstrual syndrome treatment market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the premenstrual syndrome treatment market due to the rising prevalence of premenstrual syndrome. According to the American Academy of Family Physicians, in 2020 approximately 90% of childbearing age women experience premenstrual symptoms, and less than 10% are diagnosed with the premenstrual dysphoric disorder (PMDD). The growing awareness regarding women's health shall stimulate market growth. For instance, The Office on Women's Health (OWH) within the U.S. Department of Health and Human Services (HHS) is involved in creating awareness by addressing the critical women's health issues. It helps inform and advance policies, educate professionals and consumers, and support programs related to women's health, including the premenstrual syndrome.

The Asia-Pacific is expected to have positive market growth due to many females of childbearing age. There are growing government initiatives and campaigns for improving women and maternity health. For instance, India's National Health Portal creates awareness of women's health issues, including premenstrual syndrome. The rising expenditure for improving the healthcare facilities and infrastructure shall have a positive impact on the market. Substantial market growth is expected to be observed in developing countries, including India & China.

Competitive Landscape

Bayer AG, Eli Lilly and Company, GlaxoSmithKline Plc, Pfizer Inc., H. Lundbeck A/S, Pfizer Inc., Asarina Pharma AB, Chattem, Inc. (Sanofi), Dekk-Tec, Pherin Pharmaceuticals, Novartis International AG are the leading market players with significant market share. The new product development, opportunity, and revenue generation shall intensify the market competition.

The companies use strategies such as collaborations, mergers, strategic partnerships, and acquisitions to hold their positions in the market. For instance, In Aug 2020, Bayer's acquired KaNDy Therapeutics Limited to boost their female healthcare business.

Key Companies to Watch

Bayer AG:

Overview: Bayer is a biotech and pharmaceutical multinational company. It was founded in 1863 and is headquartered in Leverkusen, Germany. Their business area includes pharmaceutical, agriculture chemicals, healthcare products and biotechnology products.

Product Portfolio:

vissane: It is a progestin medication that is generally used in birth control pills and is used to treat heavy periods and for menopausal hormone.

Key Developments: In Aug 2020, Bayer's acquired KaNDy Therapeutics Limited to boost their female healthcare business.

The global premenstrual syndrome treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers:
    • 4.1.1.1. Larger targeted population
    • 4.1.1.2. Development of therapies
  • 4.1.2. Restraints:
    • 4.1.2.1. Side-effects associated with the use of therapies
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Regulatory Analysis
• 5.3. Supply Chain Analysis
• 5.4. Pricing Analysis

6. By Drug Class

• 6.1. Introduction
  • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
  • 6.1.2. Market Attractiveness Index, By Drug Class Segment
• 6.2. Analgesics
  • 6.2.1.1. Introduction
  • 6.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 6.3. Antidepressants
• 6.4. Oral Contraceptives
• 6.5. Ovarian Suppression Agents
• 6.6. Gonadotropin-releasing hormone (GnRH) Analogues
• 6.7. Estrogen-only patches & implants
• 6.8. Selective serotonin reuptake inhibitors (SSRIs)
• 6.9. Others

7. By Distribution Channel

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 7.1.2. Market Attractiveness Index, By Distribution Channel Segment
• 7.2. Hospital Pharmacies
  • 7.2.1.1. Introduction
  • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Drug Stores and Retail Pharmacies
• 7.4. Online providers
• 7.5. Others

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.2.5.1. U.S.
    • 8.2.5.2. Canada
    • 8.2.5.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.3.5.1. Germany
    • 8.3.5.2. U.K.
    • 8.3.5.3. France
    • 8.3.5.4. Italy
    • 8.3.5.5. Spain
    • 8.3.5.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.4.5.1. Brazil
    • 8.4.5.2. Argentina
    • 8.4.5.3. Rest of South America
• 8.5. Asia Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.5.5.1. China
    • 8.5.5.2. India
    • 8.5.5.3. Japan
    • 8.5.5.4. Australia
    • 8.5.5.5. Rest of Asia Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

9. Competitive Landscape

• 9.1. Key Developments and Strategies
• 9.2. Company Share Analysis
• 9.3. Drug Classs Benchmarking
• 9.4. List of Key Companies to Watch

10. Company Profiles

• 10.1. Bayer AG
  • 10.1.1. Company Overview
  • 10.1.2. Drug Class Portfolio and Description
  • 10.1.3. Key Highlights
  • 10.1.4. Financial Overview
• 10.2. Eli Lilly And Company
• 10.3. GlaxoSmithKline Plc.
• 10.4. H. Lundbeck A/S
• 10.5. Pfizer Inc.
• 10.6. Asarina Pharma AB
• 10.7. Chattem, Inc. (Sanofi)
• 10.8. Dekk-Tec
• 10.9. Pherin Pharmaceuticals
• 10.10. Novartis International AG

LIST NOT EXHAUSTIVE

11. Global Premenstrual Syndrome Treatment Market - DataM

• 11.1. Appendix
• 11.2. About Us and End User
• 11.3. Contact Us